Core Insights - AstraZeneca reported total revenue of $58.739 billion for the year 2025, reflecting an 8% year-over-year growth at constant exchange rates. Core earnings per share reached $9.16, marking an 11% increase compared to the previous year [1]. Business Performance - The oncology segment generated $25.6 billion in revenue, a 14% increase year-over-year, accounting for 44% of total revenue. Key products include Tagrisso (osimertinib) with sales of $7.254 billion, up 10%, and Imfinzi (durvalumab) with sales of $6.063 billion, showing a significant growth of 28%. Revenue from China reached $6.654 billion, a 4% increase, representing 11% of total revenue [2]. Project Development - In 2025, the company announced positive results from 16 Phase III clinical trials and currently has 16 blockbuster drugs. It is expected to disclose over 20 Phase III trial results in 2026, with more than 100 ongoing Phase III clinical trials [3]. Future Outlook - The company anticipates mid-to-high single-digit percentage growth in total revenue for 2026, with core earnings per share expected to grow in the low double-digit percentage range. Additionally, AstraZeneca plans to invest over 100 billion RMB in China from now until 2030 to expand its presence in drug manufacturing and research and development [4].

Carillon Tower Advisers, an investment management company, released its fourth-quarter 2025 investor letter “Carillon Eagle Growth & Income Fund”. A copy of the letter can be downloaded here. 2025 marked a positive period for the equity market. The S&P 500 Index returned 2.7% in Q4 and finished the year up 17.9%. The year started with potential disruptions and heightened volatility, while it ended with optimism driven by strong AI investment, clarity in policies, and U.S. Federal Reserve (Fed) interest rate ...

阿斯利康 图源：时代财经张羽岐摄 在被带走配合调查逾一年后，阿斯利康（AZN.US）中国区前"一号人物"王磊涉骗保和走私案又有新进展。 2月12日，据媒体消息，阿斯利康前全球执行副总裁、国际业务主席及中国区总裁王磊（Leon Wang）被中国官方正式提起公诉。目前，阿斯利康方面已 向媒体证实了针对王磊的起诉书内容。 市场消息显示，指控具体案由为非法进口药物、非法收集个人信息和医疗保险欺诈。 2月12日，时代财经就上述消息的真实性及公司是否有进一步信息披露等问题采访阿斯利康方面，截至发稿暂无任何回复。 在最新披露的年报中，阿斯利康也对外表示，2025年11月，深圳市检察院完成审查，阿斯利康中国、阿斯利康一名前执行副总裁和一名前高级员工因涉嫌 非法收集个人信息、非法贸易、医保欺诈，正面临正式刑事指控。 阿斯利康并未在年报中披露涉案人员的具体姓名，但经多家媒体证实，年报中"前执行副总裁"所指的正是王磊。 阿斯利康表示，这两名前员工将在深圳市中级人民法院受审，开庭日期暂未确定。 从传奇人物到阶下囚 从2024年10月底因涉案被调查开始，王磊，这位与阿斯利康中国区紧密捆绑的高管话题不断，属于他的时代也在风波中骤然落幕。 ...

2026.02. 12 作者 | 第一财经 林志吟 本文字数：1099，阅读时长大约2分钟 2月12日，市场传出消息称，阿斯利康前全球执行副总裁、中国区总裁王磊被提起公诉。 第一财经记者向阿斯利康中国方面求证，但未获得回应。 阿斯利康在近日发布年报中曾提及称，2025年11月，深圳检方完成审查，并对阿斯利康中国、阿斯 利康一名前执行副总裁和一名前高级员工以涉嫌非法收集个人信息及非法贸易罪名提起公诉。该名前 执行副总裁和该名前高级员工还被追加医保诈骗罪名。 2025年4月，阿斯利康中国收到深圳市公安局宝安分局出具的《移送起诉告知书》，涉嫌非法收集 个人信息。 与此同时，2025年10月，阿斯利康中国也收到深圳海关的通知，告知阿斯利康中国未缴纳的进口税 总额为人民币2400万元（约350万美元）。评估意见中提到的进口税涉及度伐利尤单抗 （Imfinzi）、替西木单抗（Imjudo）和德曲妥珠单抗（Enhertu）这些药物。同月，阿斯利康自愿 全额预付补偿款。但若阿斯利康中国被判定为非法贸易责任人，其也可能被征收前述已支付进口税金 额一至五倍的罚款。 | China Personal Information | · ...

2025年4月，阿斯利康中国收到深圳市公安局宝安分局出具的《移送起诉告知书》，涉嫌非法收集个人 信息。 与此同时，2025年10月，阿斯利康中国也收到深圳海关的通知，告知阿斯利康中国未缴纳的进口税总额 为人民币2400万元（约350万美元）。评估意见中提到的进口税涉及度伐利尤单抗（Imfinzi）、替西木 单抗（Imjudo）和德曲妥珠单抗（Enhertu）这些药物。同月，阿斯利康自愿全额预付补偿款。但若阿 斯利康中国被判定为非法贸易责任人，其也可能被征收前述已支付进口税金额一至五倍的罚款。 相关案件由深圳市中级人民法院合并审理。 | China Personal Information | · In relation to the personal information infringement allegation, in April 2025, AstraZeneca | | --- | --- | | Infringement and Illegal Trade | Investment (China) Co., Ltd. received a Notice of Transfer to the P ...

Group 1 - AstraZeneca disclosed multiple lawsuits related to personal information infringement and illegal trade in its 2025 annual report [1] - In October 2025, AstraZeneca (China) received a final assessment from Shenzhen Customs indicating unpaid import taxes totaling 24 million RMB (approximately 3.5 million USD) related to specific drugs [1] - AstraZeneca (China) prepaid the compensation amount in full, but could face fines of 1 to 5 times the unpaid import tax if found liable for illegal trade [1] Group 2 - In November 2025, the Shenzhen People's Procuratorate completed its assessment, leading to public prosecution of AstraZeneca (China), a former executive vice president, and a former senior employee for illegal collection of personal information and illegal trade [1] - The former executive vice president and senior employee were additionally charged with medical insurance fraud, although AstraZeneca (China) was not prosecuted for this charge [1] - The mentioned cases have been consolidated into a single litigation process at the Shenzhen Intermediate People's Court, with no trial date scheduled yet [1]

智通财经记者 | 陈杨 智通财经编辑 | 谢欣 阿斯利康中国区相关案件又有新进展。 日前，阿斯利康发布2025年年报，其中披露阿斯利康中国及其高管关于个人信息侵权、非法贸易、医疗 保险欺诈等多项指控进展。 据年报，2025年10月，阿斯利康中国收到深圳市海关的最后评估意见，告知阿斯利康中国未缴纳的进口 税总额为人民币2400万元（约350万美元）。评估意见中提到的进口税涉及度伐利尤单抗（Imfinzi）、 替西木单抗（Imjudo）和德曲妥珠单抗（Enhertu）。同月，阿斯利康自愿全额预付补偿款。但若阿斯 利康中国被判定为非法贸易责任人，其也可能被征收前述已支付进口税金额一至五倍的罚款。 另外，2025年11月，深圳市检察院完成评估，阿斯利康中国、前执行副总裁和一名前高级雇员被指控非 法收集个人信息和非法贸易，尽管阿斯利康中国未被指控从非法收集个人信息中非法获利。前执行副总 裁和前高级雇员还被指控医疗保险欺诈。阿斯利康中国未被起诉骗保。年报称，这些事项已合并到深圳 市中级法院进行一次诉讼，开庭时间尚未可知。 针对阿斯利康中国及其高管的调查自2024年被正式公开、引发广泛关注。当年10月30日晚间，阿斯利康 ...

Core Insights - The global pharmaceutical industry has seen a reshuffling in the top 10 rankings for 2025, with Johnson & Johnson and Roche maintaining their positions at the top, while Eli Lilly has surged into the top three, driven by a 44% revenue increase from its weight-loss drug [3][12]. Group 1: Global Revenue Rankings - The top 10 pharmaceutical companies for 2025 include Johnson & Johnson with $94.19 billion, Roche with $74.43 billion, and Eli Lilly with $65.18 billion, marking a significant increase from previous years [4][13]. - Eli Lilly's revenue growth of 44% is the highest among the top companies, allowing it to surpass Merck, which has seen only a 1% increase [3][12]. Group 2: Billion-Dollar Drug Sales - Eli Lilly's Tirzepatide generated $36.5 billion in sales, making it the leading drug, followed closely by Novo Nordisk's Semaglutide at $35.5 billion [6][17]. - The emergence of GLP-1 drugs is reshaping the pharmaceutical landscape, with Eli Lilly's Tirzepatide overtaking Merck's Keytruda, which generated $31.68 billion [17]. Group 3: Performance in China - AstraZeneca leads the Chinese market with a revenue of $6.65 billion in 2025, reflecting a 4% year-over-year growth [8][20]. - Other notable performances in China include Novartis with $4.2 billion and Sanofi with $2.97 billion, while Merck's revenue has drastically declined by 66% [20]. Group 4: Future Outlook - AstraZeneca plans to invest $15 billion in China by 2030 to expand its manufacturing and R&D capabilities, highlighting the country's importance as a strategic market [20]. - The competition between GLP-1 and oncology drugs is expected to intensify, with China playing a crucial role in shaping the future of the pharmaceutical industry [21].

Ashok Leyland, Mahindra & Mahindra, LG Electronics, Lenskart Solutions, Max Financial, AstraZeneca Pharma,  Kirloskar Oil Engines, and Godrej Industries are among 344 firms scheduled to announce their earnings report for the third quarter (Q3FY26) on Wednesday.   Some other companies that are expected to declare their Q3 results today include Divi's Laboratories, Bayer CropScience, Patanjali Foods, Hindustan Motors, CARE Ratings, Protean eGov Technologies, IRCON International, and MSTC.  Oil India Q3 resu ...

Stock Market LIVE Updates, Wednesday, February 11, 2026: Indian equity benchmark indices, Indian equity benchmark indices, Sensex and Nifty , are likely to witness a positive opening on Wednesday amid mixed global cues.    As a part of the MSCI's February 2026 index review, Aditya Birla Capital and L&T Finance have been added to the MSCI Global Standard Index. IRCTC is the only Indian stock that has been excluded from the index. AU Small Finance Bank will see a weight increase in the index due to a float ad ...